Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
. These results suggest that PD-L1 on EVs may be another mechanism for glioblastoma to suppress antitumor immunity and support the potential of EVs as biomarkers in tumor patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“EVs derived from a variety of tumor types including melanoma, glioblastoma, breast, and head and neck cancer contain functional PD-L1 on their surface (Chen et al., 2018; Ricklefs et al., 2018; Theodoraki et al., 2018).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ricklefs et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“One of themost prominent molecules used by tumor cells to engage T cell immune checkpoints is programmed death ligand 1 (PD-L1) (9, 10).”
BackgroundSelf-citationSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Cited by
Items 201–300 of 632
Zhang, E., Phan, P., & Zhao, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.020 · Cited by 42
Chen, K., Duong, B. T. V., Ahmed, S. U., Dhavarasa, P., Wang, Z., Labib, M., Flynn, C. D., Xu, J., Zhang, Y. Y., Wang, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41285-8 · Cited by 45
“These fi ndings are consistent with previous investigations, indicating a decline in TIL activity is strongly associated with higher exoPD-L1 levels 6,7,23 .”
ResultHallal, S. M., Ebrahimkhani, S., Shivalingam, B., Graeber, M. B., Alexander, K. L., & Buckland, M. E. (2019) · Brain Tumor Pathology · doi:10.1007/s10014-019-00335-0 · Cited by 44
Exosomes: Powerful weapon for cancer nano-immunoengineering
Pi, Y., Xia, B.-R., Jin, M., Jin, W., & Lou, G. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114487 · Cited by 43
Wu, F., Gu, Y., Kang, B., Heskia, F., Pachot, A., Bonneville, M., Wei, P., & Liang, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1277 · Cited by 44
“According to recent studies, PD-L1 on EVs contributes to suppressing anti-tumor immunity and has the potential to serve as a biomarker in patients with cancer (24,25,27).”
Rufino-Ramos, D., Lule, S., Mahjoum, S., Ughetto, S., Cristopher Bragg, D., Pereira de Almeida, L., Breakefield, X. O., & Breyne, K. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121366 · Cited by 43
“It appears that EVs are mainly retained in the area surrounding the cells of origin and occasionally released into biofluids, such as blood, cerebrospinal fluid, and lymph, thereby reaching distant locations in the body [21,22].”
BackgroundSelf-citationAlam, M. R., Rahman, M. M., & Li, Z. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.01.026 · Cited by 42
“To describe the molecular basis of exosomal PD-L1 operated functional inhibition of CD8þ T cells, recent findings demonstrate that glioblastoma-derived exosomal PD-L1 blocks TCR-mediated T cell activation.(76) Throughout the CD8þ T cell maturation, any failure in the TCR-CD3 complex may lead the defects in CD8þ T cell…”
ResultZhou, Y., Liu, Y., Wang, Y., Hu, X., Koh, K., & Chen, H. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c01451 · Cited by 42
Extracellular vesicle-cell adhesion molecules in tumours: biofunctions and clinical applications
Lin, W., Fang, J., Wei, S., He, G., Liu, J., Li, X., Peng, X., Dai, L., Yang, S., Li, X., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01236-8 · Cited by 45
Immunopathology of Glioblastoma
Li, J., Ross, J., Hambardzumyan, D., & Brat, D. J. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-042524-025950 · Cited by 47
Miyazaki, T., Ishikawa, E., Sugii, N., & Matsuda, M. (2020) · Cancers · doi:10.3390/cancers12071960 · Cited by 44
“In addition, extracellular vesicles containing PD-L1 [45] and miRNA [46] secreted by glioma cells control the immunosuppressive ability of infiltrating immune cells.”
BackgroundDNA Associated with Circulating Exosomes as a Biomarker for Glioma
Vaidya, M., & Sugaya, K. (2020) · Genes · doi:10.3390/genes11111276 · Cited by 43
“Additionally, the elevated levels of PD-L1 DNA in circulating exosomes correlate with tumor volume, becoming a potential marker for monitoring tumor size and progression [72].”
BackgroundMiyahira, A. K., Sharp, A., Ellis, L., Jones, J. C., Kaochar, S., Larman, H. B., Quigley, D. A., Ye, H., Simons, J. W., Pienta, K. J., et al. (2019) · The Prostate · doi:10.1002/pros.23934 · Cited by 42
Tian, Y., Liu, C., Li, Z., Ai, M.-L., Wang, B., Du, K., Liu, W., Wang, H., Yu, P., Chen, C., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102454 · Cited by 42
“GL261 cell-released exosomes express PD-L1 on their surface and play an important role in blocking T cell activation and proliferation in response to T cell receptor stimulation [26].”
BackgroundSelf-citationEpithelial-mesenchymal transition in cancer stemness and heterogeneity: updated
Mortezaee, K., Majidpoor, J., & Kharazinejad, E. (2022) · Medical Oncology · doi:10.1007/s12032-022-01801-0 · Cited by 42
“There is positive correlation between PD-L1 expression with mesenchymal transcriptome profile of cancer [42], as well as a positive link between EMT induction and immunotherapy resistance.”
BackgroundExosome therapeutics for non-small cell lung cancer tumorigenesis
Orooji, N., Fadaee, M., Kazemi, T., & Yousefi, B. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03544-6 · Cited by 41
“The presence of exosomal PD-L1 significantly prevented the activation and growth of T cells in in vitro [25, 26].”
BackgroundTarin, M., Oryani, M. A., Javid, H., & Karimi‐Shahri, M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114519 · Cited by 46
The paradoxical role of IFN-γ in cancer: Balancing immune activation and immune evasion
Liu, X. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156046 · Cited by 42
The Effect of Hypoxia-Induced Exosomes on Anti-Tumor Immunity and Its Implication for Immunotherapy
Guo, W., Qiao, T., Dong, B., Li, T. X., Liu, Q., & Xu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915985 · Cited by 48
“In patients with gastric cancer, exosome-carried PDL1 resulted in decreased CD4 and CD8 T cell infiltration and activity (64).”
BackgroundEffects of glioblastoma-derived extracellular vesicles on the functions of immune cells
Musatova, O. E., & Rubtsov, Y. P. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1060000 · Cited by 42
“Interestingly, the treatment of GBM cells with low PD-L1 with IFN-γ resulted in upregulation of PD-L1 on the cell surface and on the EVs, indirectly confirming importance of PD-L1 in GBM-EVs-mediated immune suppression (Figure 3; Ricklefs et al., 2018).”
BackgroundInfluentialBurko, P., D’Amico, G., Miltykh, I. S., Scalia, F., de Macario, E. C., Macario, A. J. L., Giglia, G., Cappello, F., & Bavisotto, C. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054883 · Cited by 39
“on the surface of infiltrating T cells in the brain, inhibiting their activation and consequently promoting immunosuppression [251].”
BackgroundProbing the mechanisms of extracellular vesicle biogenesis and function in cancer
Latifkar, A., Cerione, R. A., & Antonyak, M. A. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180523 · Cited by 37
“A recent study has revealed that EVs, particularly exosomes, may be at the root of this phenomenon [48].”
BackgroundTunneling nanotubes: A bridge for heterogeneity in glioblastoma and a new therapeutic target?
Venkatesh, V. S., & Lou, E. (2019) · Cancer Reports · doi:10.1002/cnr2.1185 · Cited by 39
Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy
Ali, S., Toews, K., Schwiebert, S., Klaus, A., Winkler, A., Grunewald, L., Oevermann, L., Deubzer, H. E., Tüns, A. I., Jensen, M. C., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00531 · Cited by 41
“Neuroblastoma TEVs Do Not Impair CAR T Cell Viability Since TEVs have been reported to modify immune effector functions (33, 34), we investigated the impact of extracellular vesicles derived from the human SH-SY5Y neuroblastoma cell line, which is lacking neurotrophin receptor expression, or neurotrophin-expressing mo…”
BackgroundPersano, S., Vicini, F., Poggi, A. D., Fernandez, J. L. C., Rizzo, G. M. R., Gavilán, H., Silvestri, N., & Pellegrino, T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101668 · Cited by 37
“Brain tumor cells can directly inhibit immune responses by regulating the expression of specific surface proteins, including programmed death-ligand 1 (PD-L1), cluster of differentiation 47 (CD47), human leukocyte antigen (HLA) molecules and natural killer group 2 member D (NKG2D) ligands, or indirectly through the se…”
BackgroundZhao, M., Mi, D., Ferdows, B. E., Li, Y., Wang, R., Li, J., Patel, D. N., Kong, N., Shi, S., & Tao, W. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101361 · Cited by 37
Zhao, X., Hu, S., Zeng, L., Liu, X., Song, Y., Zhang, Y., Chen, Q., Bai, Y., Zhang, J., Zhang, H., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104690 · Cited by 37
Silver, A., Feier, D., Ghosh, T., Rahman, M., Huang, J., Sarkisian, M. R., & Deleyrolle, L. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1022716 · Cited by 42
Qin, Z., Xu, Q., Hu, H., Yu, L., & Zeng, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00724 · Cited by 36
Role of Tumor-Derived Extracellular Vesicles in Glioblastoma
Chen, Y., Jin, Y., & Wu, N. (2021) · Cells · doi:10.3390/cells10030512 · Cited by 36
Huang, D., Chen, J., Hu, D., Xie, F., Yang, T., Li, Z., Wang, X., Xiao, Y., Zhong, J., Jiang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675940 · Cited by 36
“A study showed that glioblastoma-released sEVs expressing PD-L1 inhibited the activation and proliferation of CD4 T and CD8 T cells by binding to PD-1, leading to immune escape of glioblastoma cells (32).”
BackgroundDiagnostic potential of extracellular vesicles in meningioma patients
Ricklefs, F. L., Maire, C. L., Wollmann, K., Dührsen, L., Fita, K. D., Sahm, F., Herold‐Mende, C. C., von Deimling, A., Kolbe, K., Holz, M., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac127 · Cited by 35
Self-citationQin, Z., Hu, H., Sun, W. C., Chen, L., Jin, S., Xu, Q., Liu, Y., Yu, L., & Zeng, S. (2021) · Cancers · doi:10.3390/cancers13040618 · Cited by 35
Wei, F., Fang, R., Lyu, K., Liao, J., Long, Y., Yang, J., Wen, W., & Sun, W. (2023) · Oral Oncology · doi:10.1016/j.oraloncology.2023.106532 · Cited by 35
Tumor‐derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer
Wu, Y., Fu, H., Hao, J., Yang, Z., Qiao, X., Li, Y., Zhao, R., Lin, T., Wang, Y., & Wang, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1342728 · Cited by 41
“They found that exosomal PD-L1 levels were elevated in NSCLC patients, especially in advanced stages, compared to healthy controls (51).”
BackgroundKansha, T., Ma, S., Wang, H., Yu, X., Song, Y., Guo, Z., Song, J., Xue, L., & Yang, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603855 · Cited by 37
“This membrane topology conservation ensures that exo PD-L1 retains its ability to engage PD-1 receptors on recipient T cells, thereby mediating immunosuppressive interactions post-secretion (9, 23, 24).”
Extracellular Vesicles Orchestrate Immune and Tumor Interaction Networks
Yim, K. H. W., Hrout, A. A., Borgoni, S., & Chahwan, R. (2020) · Cancers · doi:10.3390/cancers12123696 · Cited by 33
“As a result, intercellular signaling via EVs has been shown to elicit either positive or negative immune responses, including immune suppression or evasion [4].”
BackgroundGlioma-Derived Extracellular Vesicles – Far More Than Local Mediators
Tankov, S., & Walker, P. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679954 · Cited by 36
“PD-L1 serum and plasma droplet PCR (66)”
BackgroundIndoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated
Charehjoo, A., Majidpoor, J., & Mortezaee, K. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110032 · Cited by 34
Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
Rao, D., Huang, D., Si, M.-Y., Lu, H., Tang, Z., & Zhang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1142539 · Cited by 35
“(28) screened 85 patients with newly diagnosed NSCLC and 27 healthy subjects as the study subjects, and analyzed the correlation between the immunohistochemical characteristics of exoPD-L1, sPD-L1 and PD-L1 and the clinicopathological characteristics.”
BackgroundEmerging extracellular vesicle-based carriers for glioblastoma diagnosis and therapy
Wang, J., Liu, Y., Liu, F., Gan, S., Roy, S., Hasan, I., Zhang, B., & Guo, B. (2023) · Nanoscale · doi:10.1039/d3nr01667f · Cited by 33
Jung, M. K., Aibaidula, A., Brown, D. A., Himes, B. T., Garcia, L. M. C., & Parney, I. F. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac017 · Cited by 45
Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics
Le, I., Dhandayuthapani, S., Chacon, J. A., Eiring, A. M., & Gadad, S. S. (2022) · Vaccines · doi:10.3390/vaccines10050816 · Cited by 35
“Cancer immune evasion can also be achieved through the binding of programmed death ligand-1 (PD-L1) or -2 (PD-L2) on the cancer cells to programmed cell death protein-1 (PD-1) on the surface of T cells, which inhibits T cell activation by inducing T cell exhaustion [35,36].”
BackgroundTadokoro, H., Hirayama, A., Kudo, R., Hasebe, M., Yoshioka, Y., Matsuzaki, J., Yamamoto, Y., Sugimoto, M., Soga, T., & Ochiya, T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231430 · Cited by 32
Sharifzad, F., Yasavoli‐Sharahi, H., Mardpour, S., Fakharian, E., Nikuinejad, H., Heydari, Y., Mardpour, S., Taghikhani, A., khellat, R., Vafaei, S., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28813 · Cited by 31
“Regardless of cell death etiology, a central pallor forms and it seems that evasion of tumor cells from poorly oxygenated central regions caused a garland like arrangement of the disorganized loop of hypercellular tumor nuclei around the central pale area, which associate with tumor necrosis (PNN; Ricklefs et al., 201…”
BackgroundTransformable vesicles for cancer immunotherapy
Wang, S., Hu, X., Wei, W., & Ma, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113905 · Cited by 32
Zhu, F., Ji, Y., Deng, J., Li, L., Bai, X., Liu, X., Lin, B., & Lu, Y. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.09.058 · Cited by 32
Liang, B., Hu, X., Ding, Y., & Liu, M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30197 · Cited by 30
“The latest studies manifest that TEXs bearing PD‐L1 on their surface directly interact with T cells and aggravate immunosuppression (Ricklefs et al., 2018; Yang et al., 2018), which inevitably uncovers a mechanism of TEX‐mediated PD‐1/PD‐L1 axis.”
BackgroundInfluentialIrshad, K., Srivastava, C., Malik, N., Arora, M., Gupta, Y., Goswami, S., Sarkar, C., Suri, V. S., Mahajan, S., Gupta, D. K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.813888 · Cited by 33
“This indicates some secretory product in high FAT1-expressing glioma cell supernatant that affects the polarization of THP-1 cells (19, 68).”
BackgroundImmunogenetics of glioblastoma: the future of personalized patient management
Abedalthagafi, M., Barakeh, D. H., & Foshay, K. M. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0070-1 · Cited by 31
“Recent data also suggest that extracellular vesicles that shed from GBM cells can bind PD-1, potentially independent of PD-L1 expression on their surface, to suppress T cell activation.(75) GBM is also associated with lymphocytes and Tregs that constitutively express the surface receptor CTLA-4.”
BackgroundBerzaghi, R., Islam, A., Hellevik, T., & Martínez-Zubiaurre, I. (2021) · Journal of Radiation Research · doi:10.1093/jrr/rrab018 · Cited by 33
Research Progress in the Application of Exosomes in Immunotherapy
Zhang, X., Xu, D., Song, Y., Rong, H., & Wang, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.731516 · Cited by 31
“(82) first identified glioblastoma exosomes containing PD-L1 and blocking TCR-induced T-cell activation.”
BackgroundXiao, B.-L., Wang, X.-L., Xia, H.-F., Zhang, L., Wang, K.-M., Chen, Z.-K., Zhong, Y., Jiang, H.-G., Zhou, F., Wang, W., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0277 · Cited by 31
Rausch, L., Flaskamp, L., Ashokkumar, A., Trefzer, A., Ried, C., Buchholz, V. R., Obst, R., Straub, T., Brocker, T., & Kranich, J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210047120 · Cited by 31
A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications
Knox, M. C., Ni, J., Bece, A., Bucci, J. A., Chin, Y. S., Graham, P., & Li, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01612 · Cited by 31
Park, S., Kim, J., Lee, C., Bae, J.-H., Park, J., Choe, E., & Baek, M. (2022) · Cancers · doi:10.3390/cancers14174081 · Cited by 28
DNA Nanomaterial‐Empowered Surface Engineering of Extracellular Vesicles
Yao, X., He, D., Wei, P., Niu, Z., Chen, H., Li, L., Fu, P., Wang, Y., Lou, S., Qian, S., et al. (2023) · Advanced Materials · doi:10.1002/adma.202306852 · Cited by 29
Wang, G., He, L., Wang, S., Zhang, M., Li, Y., Liu, Q., Sun, N., Zhang, X., Liu, Y., Zhang, J., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa309 · Cited by 28
Khalafallah, A. M., Huq, S., Jimenez, A. E., Serra, R., Bettegowda, C., & Mukherjee, D. R. (2020) · Neurosurgery · doi:10.1093/neuros/nyaa305 · Cited by 28
Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment
Hu, L., Sun, C., Yuan, K., & Yang, P. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104181 · Cited by 30
Rodvold, J. J., Su, X., Nussbacher, J. K., Tsui, B., Waller, T. C., Searles, S. C., Lew, A., Jiang, P., Babić, I., Nomura, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65320-6 · Cited by 28
Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?
Sayed, R. E., Haibe, Y., Amhaz, G., Bouferraa, Y., & Shamseddine, A. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042142 · Cited by 30
Simionescu, N., Zonda, R., Petrovici, A. R., & Georgescu, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13070988 · Cited by 29
Glioma EVs Contribute to Immune Privilege in the Brain
Abels, E. R., Broekman, M. L. D., Breakefield, X. O., & Maas, S. L. N. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.05.006 · Cited by 30
Self-citationThe Quest for Non-Invasive Diagnosis: A Review of Liquid Biopsy in Glioblastoma
Elias, M. G., Hadjiyiannis, H., Vafaee, F., Scott, K. F., SOUZA, P. D., Becker, T. M., & Fatima, S. (2025) · Cancers · doi:10.3390/cancers17162700 · Cited by 31
Xu, Q., Liang, Y., Huang, L., Zhou, L. Q., Chen, X., Ye, M., Wu, G., Zhan, P., Lv, T., & Song, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s291611 · Cited by 28
Liquid biopsy: early and accurate diagnosis of brain tumor
Yi, Z., Qu, C., Zeng, Y., & Liu, Z. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04011-3 · Cited by 31
A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression
Tzaridis, T., Weller, J. M., Bachurski, D., Shakeri, F., Schaub, C., Hau, P., Buneß, A., Schlegel, U. S., Steinbach, J. P., Seidel, C., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34261 · Cited by 27
A key driver to promote HCC: Cellular crosstalk in tumor microenvironment
Liu, P., Lingyu, K., Liu, Y., Li, G., Xie, J., & Lu, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135122 · Cited by 30
“A previous study suggested that PD-L1 is of importance for TDEs-mediated CD8T cells suppression (53).”
ResultJha, A., Alam, M., Kashyap, T., Nath, N., Kumari, A., Pramanik, K. K., Nagini, S., & Mishra, R. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110894 · Cited by 30
Primorac, D., Brlek, P., Bulić, L., Hrvatin, N., Škaro, V., Projić, P., Glavan, M., Oleru, I., Rocheteau, P., Tremolada, C., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041676 · Cited by 31
“Firstly, Chen et al. and Ricklefs et al., studying metastatic melanoma and glioblastoma, respectively, found that exosomal-surface PD-L1 can directly suppress the immune response by directly interacting with T-cell surface receptor PD-1 [185,186].”
Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer
Li, G., Wang, G., Chi, F., Jia, Y., Wang, X., Mu, Q., Qin, K., Zhu, X., Pang, J., Xu, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002218 · Cited by 37
“…as a novel treatment strategy for advanced GC. 15 16 Subsequently, extracellular PD-L1 (ePD-L1), including soluble PD-L1 (sPD-L1) 17–19 and extracellular vesicular (EV) ePD-L1, 20 21 has been characterized and was proved to be associated with anti- PD-L1/PD-1 therapy in different solid tumors.”
Zhang, J., Qin, Y., Jiang, Q., Li, F., Jing, X., Cao, L. K., Cai, S., Wu, F., Li, Q., Lian, J., et al. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00159 · Cited by 25
Yu, C., Hsieh, K., Cherry, D. R., Nehlsen, A. D., Salgado, L. R., Lazarev, S., & Sindhu, K. K. (2023) · Biology · doi:10.3390/biology12121528 · Cited by 29
Extracellular Vesicles and Artificial Intelligence: Unique Weapons against Breast Cancer
Serretiello, E., Smimmo, A., Ballini, A., Parmeggiani, D., Agresti, M., Bassi, P., Moccia, G., Sciarra, A., Angelis, A. D., Monica, P. D., et al. (2024) · Applied Sciences · doi:10.3390/app14041639 · Cited by 25
“Microvesicles derived from tumoral endothelial miR-9 cells were re-ported to promote not only MV-induced endothelial cell migration but also tumor angiogenesis [42–47].”
BackgroundBertero, L., Siravegna, G., Rudà, R., Soffietti, R., Bardelli, A., & Cassoni, P. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12553 · Cited by 26
Exosome and Secretion: Action On?
Hu, Y., Zhang, R., & Chen, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_19 · Cited by 27
Gool, S. V., Makalowski, J., Bonner, E. R., Feyen, O., Domogalla, M. P., Prix, L., Schirrmacher, V., Nazarian, J., & Stuecker, W. (2020) · Medicines · doi:10.3390/medicines7050029 · Cited by 25
“PDL1 positivity in these CTCs might contribute to immune resistance, similar to the mechanism published for PDL1-expressing GBM-derived extracellular vesicles [58].”
BackgroundThe role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects?
Yin, T., Xin, H., Yu, J., & Teng, F. (2021) · Biomarker Research · doi:10.1186/s40364-021-00277-w · Cited by 25
Tumor‐derived exosomal PD‐L1 in progression of cancer and immunotherapy
Rasihashemi, S. Z., Rezazadeh‐Gavgani, E., Majidazar, R., Seraji, P., Oladghaffari, M., Kazemi, T., & Lotfinejad, P. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30645 · Cited by 26
“PD‐L1‐containing exosomes derived from glioblastoma stem cells could promote tumor progression by inhibiting both CD4+ and CD8+ T‐cells activation (Ricklefs et al., 2018).”
BackgroundInfluentialRecent Progress in Extracellular Vesicle-Based Carriers for Targeted Drug Delivery in Cancer Therapy
Tang, Y., Liu, X., Sun, M., Xiong, S., Xiao, N., Li, J., He, X., & Xie, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071902 · Cited by 24
Extracellular vesicles as biomarkers and drug delivery systems for tumor
Wang, X., Chen, W., Zeng, W., Feng, K., Zheng, Y. F., Wang, P., Chen, F., Zhang, W., Di, L., & Wang, R. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.04.033 · Cited by 26
“TDEVs can stimulate nuclear factor k B (NF-k B) or intervene in the PD-L1/PD-1 axis to support tumor immune evasion 117 .”
Crow, J., Samuel, G., & Godwin, A. K. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1688144 · Cited by 25
Lopatina, T., Koni, M., Grange, C., Cedrino, M., Femminò, S., Lombardo, G., Favaro, E., & Brizzi, M. F. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106206 · Cited by 25
Lucien, F., Kim, Y., Qian, J., Orme, J. J., Zhang, H., Arafa, A., Abraha, F., Thapa, I., Tryggestad, E. J., Harmsen, W. S., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.05.037 · Cited by 25
Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer
Setayesh, S. M., Hart, O., Naghdloo, A., Higa, N., Nieva, J. J., Lu, J. M., Hwang, S. E., Wilkinson, K., Kidd, M., Anderson, A. K. L., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00480-4 · Cited by 25
Clinical Theranostics Trademark of Exosome in Glioblastoma Metastasis
Nag, S., Bhattacharya, B., Dutta, S., Mandal, D., Mukherjee, S., Anand, K., Eswaramoorthy, R., Thorat, N. D., Jha, S. K., & Gorai, S. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00212 · Cited by 26
What is the burden of proof for tumor mutational burden in gliomas?
Khasraw, M., Walsh, K. M., Heimberger, A. B., & Ashley, D. M. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa256 · Cited by 28
Rudsari, H. K., Veletić, M., Bergsland, J., & Balasingham, I. (2021) · IEEE Transactions on NanoBioscience · doi:10.1109/tnb.2021.3097698 · Cited by 28
“EVs may lead the way to targeted drug delivery and immune- and genetherapy [8], [34], [35].”
BackgroundExosome-Mediated Crosstalk Between Cancer Cells and Tumor Microenvironment
Saad, S. H., Kashanchi, A., Zadeh, M. A., Williams, A., & Batrakova, E. V. (2025) · Cells · doi:10.3390/cells14221750 · Cited by 30
Cellular Conversations in Glioblastoma Progression, Diagnosis and Treatment
Sisakht, A. K., Malekan, M., Ghobadinezhad, F., Firouzabadi, S. N. M., Jafari, A., Mirazimi, S. M. A., Abadi, B., Shafabakhsh, R., & Mirzaei, H. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01212-9 · Cited by 24
“T cells can be targets of EVs produced by GBM cells, and their activation can be inhibited as a result of this interaction (Grimaldi et al.”
BackgroundInfluentialProteomic profiling in extracellular vesicles for cancer detection and monitoring
Xue, V. W., Yang, C., Wong, S. C. C., & Cho, W. C. S. (2021) · PROTEOMICS · doi:10.1002/pmic.202000094 · Cited by 25
Billerhart, M., Schönhofer, M., Schueffl, H. H., Polzer, W., Pichler, J., Decker, S., Taschauer, A., Maier, J., Anton, M., Eckmann, S., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.09.005 · Cited by 23
“However, PD-L1 overexpression on tumor cells and its interaction with programmed cell death 1 (PD-1) receptor on T cells suppresses their inflammatory and hence antitumoral response.(3) CD47 (integrin-associated protein [IAP]), a ubiquitously expressed transmembrane glycoprotein, acts as a “marker of self” and plays a…”
BackgroundRony, R. M. I. K., Shokrani, A., Malhi, N. K., Hussey, D. M., Mooney, R., Chen, Z. B., Scott, T. A., Han, H., Moore, J., Liu, J., et al. (2025) · Biomolecules · doi:10.3390/biom15071000 · Cited by 25
Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis
Vathiotis, I. A., Gomatou, G., Stravopodis, D. J., & Syrigos, N. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105383 · Cited by 23
“PD-L1-containing exosomes have been involved in tumor progression in preclinical malignant glioma models; exosomal PD-L1 secreted by glioblastoma stem-like cells inhibited the activation of CD4+ and CD8+ immune effector cells [38].”
BackgroundRackles, E., Lopez, P. H., & Falcón‐Pérez, J. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.004 · Cited by 22
Wan, C., Stowell, M. H. B., & Shen, J. (2022) · Communications Biology · doi:10.1038/s42003-022-04050-z · Cited by 23
Kumari, S., Bandyopadhyay, B., Singh, A., Aggarwal, S., Yadav, A. K., Vikram, N. K., Guchhait, P., & Banerjee, A. K. (2023) · mBio · doi:10.1128/mbio.01823-23 · Cited by 24
“Multiple studies suggest that the role of IFNγ is crucial in regulating the PD-L1 expression via the IFNγ/PD-L1 axis (35–37).”
BackgroundAlternative immune checkpoints in immunoregulatory profile of cancer stem cells
Mortezaee, K., & Majidpoor, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23171 · Cited by 25
“Glioblastoma (GBM) CSC-derived extracellular vesicles (EVs) containing low amount of PD-L1 represent high levels of IDO1, which is suggestive of multiple layers of immune regulation in such tumor type [44].”
BackgroundMantile, F., Franco, P., Stoppelli, M. P., & Liguori, G. L. (2020) · Advances in biomembranes and lipid self-assembly · doi:10.1016/bs.abl.2020.05.006 · Cited by 24
Metadata
- Authors
- Ricklefs, F. L., Alayo, Q., Krenzlin, H., Mahmoud, A. B., Speranza, M. C., Nakashima, H., Hayes, J. L., Lee, K., Balaj, L., Passaro, C., Rooj, A. K., Krasemann, S., Carter, B. S., Chen, C. C., Steed, T., Treiber, J., Rodig, S., Yang, K., Nakano, I., Lee, H., Weissleder, R., Breakefield, X. O., Godlewski, J., Westphal, M., Lamszus, K., Freeman, G. J., Bronisz, A., Lawler, S. E., & Chiocca, E. A.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Berkeley (US)
- Massachusetts General Hospital (US)
- University Medical Center Hamburg-Eppendorf (DE)
- University of California San Diego (US)
- Comprehensive Cancer Center, University of Birmingham, Birmingham, AL 35294, USA.
- Harvard University (US)
- Corresponding author
- Lawler, Sean E.
- Chiocca, E. Antonio
- ORCID
- Ricklefs, Franz L.
- Alayo, Quazim
- Krenzlin, Harald
- Mahmoud, Ahmad B.
- Speranza, Maria C.
- Nakashima, Hiroshi
- Hayes, Josie L.
- Lee, Kyungheon
- Balaj, Leonora
- Passaro, Carmela
- Rooj, Arun K.
- Krasemann, Susanne
- Carter, Bob S.
- Chen, Clark C.
- Steed, Tyler
- Treiber, Jeffrey
- Rodig, Scott
- Yang, Katherine
- Nakano, Ichiro
- Lee, Hakho
- Weissleder, Ralph
- Breakefield, Xandra O.
- Godlewski, Jakub
- Westphal, Manfred
- Lamszus, Katrin
- Freeman, Gordon J.
- Bronisz, Agnieszka
- Lawler, Sean E.
- Chiocca, E. Antonio
- Venue
- Science Advances
- Published
- 2018-03-02
- Volume
- 4
- Issue
- 3
- Pages
- eaar2766-eaar2766
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC5842038
- OpenAlex
- W2793992337
- Cited by
- 610
- References
- 42
- Citations by year
- 2026: 48 · 2025: 68 · 2024: 76 · 2023: 76 · 2022: 85 · 2021: 111 · 2020: 75 · 2019: 56 · 2018: 15
- FWCI
- 22.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Science Advances (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (CA176203-01A1)
- National Cancer Institute (P01 CA69246)
- Deutsche Forschungsgemeinschaft (RI 2616/1-1, RI 2616/2-1)
- National Institute of Health (NCI P01 CA69246)
- American-Italian Cancer Foundation Post-doctoral Research Fellowship
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- glioblastoma, PD-L1, extracellular vesicles, immune evasion, antitumor immunity, tumor microenvironment, biomarkers
- MeSH terms
- Extracellular Vesicles, Antigens, Neoplasm, Brain Neoplasms, Glioblastoma, Humans, Interferon-gamma, Lymphocyte Activation, Receptors, Antigen, T-Cell, T-Lymphocytes, Neoplastic Stem Cells, Up-Regulation, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Immune Evasion, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.